Autoimmune disease therapy - Novartis

Drug Profile

Autoimmune disease therapy - Novartis

Alternative Names: NVS antibodies - Novartis

Latest Information Update: 30 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders

Most Recent Events

  • 30 Sep 2009 Discontinued - Phase-I for Autoimmune disorders in Germany (unspecified route)
  • 26 Apr 2006 This compound is still in active development
  • 17 Jan 2003 Phase-I clinical trials in Autoimmune disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top